In an effort to provide you with timely market feedback from ASCO 2015, OBR and MDoutlook are pleased to share results from MDoutlook’s OncoPolls™ from the meeting. This first report explored presentations concerning the anti-PD-1 / PD-L1 antibody-based Immune Checkpoint Inhibitors in non-small cell lung cancer (NSCLC).
Geographic Distribution of Respondents
Attendance at 2014 ASCO Annual Meeting
Survey Participants’ NSCLC Cancer Patient Flow:
Average Nearly 20 Cases Each Month
* Survey Participants = Medical Oncologists with an identified clinical interest in NSCLC
Expected Usage of Immune Checkpoint Blockade Antibodies in Non-Mutated NSCLC
Expected Usage of Immune Checkpoint Blockade Antibodies in NSCLC with Driver Mutations
Dual Immune Checkpoint Blockade in NSCLC
Perceived Value of Immune Checkpoint Blockade Antibodies in NSCLC
Conclusions: Impact of ASCO 2015 on Immune Checkpoint Inhibitors for Lung Cancer
For a more detailed analysis report, please click here to download the full report.
Submitted by Robert Stephan, Sr. Director Medical Services and Strategy, and Jan Heybroek, President MDoutlook.
You must be logged in to post a comment